Prognostic role of serum carcinoembryonic antigen in patients receiving liver resection for colorectal cancer liver metastasis: A meta-analysis

Table 1 Basic features of the included literature

No.	Ref.	Country	Study type	Treatment	Univariate/multivariate analysis	Cut-off (ng/mL)	Sample size	Age	Male/female	Outcomes	Nos
1	Meng et al[34], 2021	China	Cohort study	Hepatectomy + chemotherapy	Multivariate	100	234	Range (n): < 65, 164; ≥ 65, 70	126/108	OS	9
2	Okimoto et al[35], 2017	Japan	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	134	Median (range): 63 (30-87)	90/44	OS	8
3	Kamphues et al[53], 2021	Germany	Cohort Study	Hepatectomy	Multivariate	6.15	1643	Median (range): 62 (18-90)	1018/625	OS	7
4	Kawahara et al[36], 2018	Japan	Cohort study	Hepatectomy	Univariate	5/50	66	Median (range): 65.2 (31-80)	45/21	RFS	7
5	Hof et al[54], 2016	The Netherlands	Cohort study	Hepatectomy	Multivariate	200	431	mean ± SD: 62.9 ± 9.4	264/167	OS	8
6	Chiang et al[37], 2019	China	Cohort study	Hepatectomy + chemotherapy	Multivariate	5	490	Median (range): 60.3 (28.8-88.0)	332/158	RFS, OS	8
7	Peltonen et al[55], 2018	Finland	Cohort study	Hepatectomy + chemotherapy	Univariate	5	168	Median (range): 64.3 (36.3-81.5)	101/67	OS, DFS	8
8	Lu et al[38], 2016	China	Cohort study	Hepatectomy + chemotherapy	Univariate	5	141	Median (range): 60 (20-82)	92/49	OS	7
9	John et al[56], 2013	United Kingdom	Cohort study	Hepatectomy + chemotherapy	Univariate	200	432	Median (range): 64.5 (29-85)	289/143	OS	7
10	Yi et al[39], 2013	Korea	Cohort study	Hepatectomy + chemotherapy	Multivariate	5	76	Median (range): 57(31-75)	47/29	DFS	8
11	Gervaz et al[57], 2000	Switzerland	Cohort study	Hepatectomy	Univariate	4	49	≥ 18	35/14	OS	7
12	Sasaki et al[40], 2005	Japan	Cohort study	Hepatectomy	Multivariate	10	103	Range (n): ≤ 32, 164; > 60, 71	56/47	OS	9
13	Wang et al[41], 2017	China	Cohort study	Hepatectomy + chemotherapy	Multivariate	5	159	Median (range): Non-targeted therapy group 52 (35-83); bevacizumab combined treatment group 43 (32-71); cetuximab combined treatment group 59 (28-76)	101/58	RFS, OS	8
14	Takamizawa et al[42], 2022	Japan	Cohort study	Hepatectomy	Multivariate	5	554	Median (range): 62 (21-88)	358/196	RFS, OS	9
15	Masuda et al[64], 2018	United States	Cohort study	Hepatectomy + RFA	Multivariate	30	116	mean ± SD: tumors ≥ 4, 58.7 ± 10.6; tumors < 4, 57.6 ± 12.0	74/42	OS	7
16	Zhang et al[43], 2017	China	Cohort study	Hepatectomy	Multivariate	100	102	Range (n): < 60, 66; ≥ 60, 36	63/39	OS	9
17	Ishii et al[44], 2022	Japan	Cohort study	Hepatectomy	Univariate	5	90	Median (range): High CII 65 (31-87); low CII 65 (32-82)	58/32	RFS, OS	7
18	Tanaka et al[45], 2008	Japan	Cohort study	Hepatectomy + chemotherapy	Multivariate	12	79	Range (n): ≥ 60, 46; < 60, 33	49/30	OS	9
19	Sasaki et al[65], 2016	United States	Cohort study	Hepatectomy + RFA	Multivariate	30	485	Median (IQR): 58.5 (49.1-66.5)	290/195	OS	8
20	Chen et al[46], 2020	China	Cohort study	Hepatectomy + chemotherapy	Univariate	10	141	Median (IQR): 55 (49.0-62.0)	92/49	PFS, OS	7
21	Montalti et al[58], 2015	Belgium	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	114	mean ± SD: 66.4 ± 0.89	78/36	OS, RFS	6
22	Reddy et al[67], 2009	United States	Cohort study	Hepatectomy + chemotherapy	Multivariate	200	499	Median (range): 57(49-66)	294/205	OS	6
23	Reddy et al[66], 2009	United States	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	230	Median (range): 61(33-83)	137/93	OS	7
24	Li et al[47], 2023	China	Cohort study	Hepatectomy + chemotherapy	Univariate	200	431	Median (IQR): 59 (49-68)	282/149	RFS, OS	7
25	Niu et al[68], 2007	Australia	Cohort study	Hepatectomy	Multivariate	5	315	mean ± SD: 62 ± 11	239/176	OS	6
26	Polivka et al[59], 2020	The Czech Republic	Cohort study	Hepatectomy	Multivariate	4.9	71	Median (range): 62.7 (29-77)	29/42	DFS, OS	6
27	Takeda et al[48], 2022	Japan	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	238	Range (n): < 60, 123; ≥ 60, 115	184/54	OS	8
28	Dumarco et al[69], 2023	Brazil	Cohort study	Hepatectomy	Multivariate	20	137	Median (range): 58.2 (23-87)	75/62	OS, DFS	8
29	Kim et al[49], 2019	Korea	Cohort study	Hepatectomy + chemotherapy	Multivariate	100	83	mean ± SD: 59.5 ± 10.0	62/21	OS	8
30	Peng et al[50], 2017	China	Cohort study	Hepatectomy	Univariate	200	150	Median (range): 58 (20-82)	97/53	RFS, OS	7
31	Imai et al[60], 2016	France	Cohort study	Hepatectomy	Multivariate	50	846	Median (range): 61 (28-89)	502/344	OS	8
32	Pawlik et al[61], 2005	Switzerland	Cohort study	Hepatectomy	Multivariate	200	566	Median 60	221/345	OS	6
33	Miki et al[51], 2018	Japan	Cohort study	Hepatectomy	Multivariate	5	73	Median (range): 59 (27-82)	49/24	DFS	8
34	Hohenberger et al[62], 1994	Germany	Cohort study	Hepatectomy	Univariate	5	166	Median (range): 59 (30-79)	99/67	OS	7
35	Arru et al[65], 2008	Italy	Cohort study	Hepatectomy	Multivariate	5/200	297	Range (n): < 65, 177; ≥ 65, 120	171/126	OS	8
36	Yoshino et al[52], 2022	Japan	Cohort study	Hepatectomy	Multivariate	5	633	Median (range): 64.0 (27.0-92.0)	414/219	RFS, OS	8

OS: Overall survival; DFS: Disease-free survival; RFS: Recurrence-free survival; IQR: Interquartile range; RFA: Radiofrequency ablation; PFS: Progression-free survival.